The Top 5 Biosimilars Articles for the Week of November 18
The Center for Biosimilars® recaps the top stories for the week of November 18, 2019.
Transcript
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 18, 2019.
Number 5: The first patients in a phase 3 trial of PB006, a proposed natalizumab biosimilar, have begun to receive the study drug.
Number 4: Samsung Bioepis announced that the FDA has accepted for review a Biologics License Application for SB8, a proposed bevacizumab biosimilar referencing Avastin.
Number 3: While much attention over the past few weeks has been on the US biosimilars market, Canada has also been making strides in its own biosimilars experience.
Number 2: The US market saw the launch of the third biosimilar pegfilgrastim.
Number 1: The FDA approved Pfizer’s adalimumab biosimilar, referencing Humira.
Finally, last week, our e-newsletter asked whether you think that the 10% list price discount for the first US rituximab biosimilar is deep enough to drive uptake.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Eye on Pharma: Bevacizumab Update; Samsung Bioepis, J&J Settlement; Another EU Trastuzumab
December 6th 2023Outlook Therapeutics provides an update on the development of its bevacizumab candidate for age-related macular degeneration; Samsung Bioepis settles with Johnson & Johnson (J&J) over its ustekinumab biosimilar candidate; and the European Union gains another trastuzumab biosimilar.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
